Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AH23844 (lavoltidine)
AH23844 · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| AH23844 (lavoltidine) | DRUG | - |
| NEXIUM (esomeprazole) | DRUG | - |
| ZANTAC (ranitidine) | DRUG | - |
Inclusion criteria: * Subject must have a Body Mass Index (BMI) from 19-30 kg/m2 * Subject does not present with abnormal clinical lab findings * Subject is able to tolerate a nasogastric pH electrode. Exclusion criteria: * Subject is Helicobacter-positive on a C13 urea breath test * Subject has ...
AH23844 is an investigational small molecule developed for gastroesophageal reflux disease, also known as GERD or acid reflux. It was studied in a Phase 2 clinical trial in adults with gastroesophageal reflux disease. It is not an approved therapy and remains in clinical development.
AH23844 is being developed by GSK plc, which trades under the ticker GSK. The company sponsored the Phase 2 study of the compound in gastroesophageal reflux disease. GSK holds the development program for this asset.
AH23844 is in Phase 2 development. One Phase 2 trial has been completed, and no trials are currently active. The drug is investigational and has not been approved for any indication.
AH23844 has been studied in one completed Phase 2 trial, NCT00405119, titled a study to investigate the effectiveness of AH234844 (lavoltidine) compared with NEXIUM and ranitidine. The trial enrolled 92 participants in Australia, was randomized and double blind, and included healthy male volunteers aged 18 years and older.
Yes, AH23844 is also known as lavoltidine. The two names refer to the same investigational small molecule studied for gastroesophageal reflux disease. Searches for either name lead to the same GSK development program.
AH23844 was studied as a treatment for gastroesophageal reflux disease, a condition in which stomach contents flow back into the esophagus. The completed Phase 2 trial compared it with NEXIUM and ranitidine in 92 participants. It is investigational and not approved for use.